Research Summary

Analyzed using Evidence Intelligence™

Incretins show little effect on insulin clearance in type 2 diabetes

Last updated September 12, 2026

Key finding

Insulin clearance showed some differences between sitagliptin and metformin treatment (p < 0.02).

This randomized controlled trial investigated the effects of incretin-based therapies on insulin clearance in type 2 diabetes. It found significant differences in insulin clearance between treatments.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

Clinical relevance

Understanding how different diabetes medications impact insulin clearance is crucial for optimizing treatment strategies in type 2 diabetes. The findings may help clinicians tailor therapies to improve patient outcomes, particularly in managing blood glucose levels and insulin sensitivity.

Keep in mind

Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Potential confounding factors were not fully controlled.

Published in

Journal Reference

Publication details and source links for this paper.

Andrea T, Christian G, Irfan V, Giovanni P, Michael N. Incretins and insulin clearance in type 2 diabetes: a randomized controlled trial. Scientific Reports. 2022;12:2510. doi:10.1038/s41598-022-06402-5

View DOI View on PubMed View on PMC

Main Effects

Insulin clearance showed significant differences between sitagliptin and metformin (p < 0.02).

Total insulin secretion was significantly higher during OGTT compared to IIGI (p < 0.0001).

Plasma glucose levels were significantly reduced during the intervention (p < 0.01).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to GIP, GLP-1 receptor agonists, GLP-1/GIP Combination, and 3 more and C-peptide, Blood glucose, Total GIP, and 3 more.

This study contributes evidence to

Intervention

GIP

Outcome

C-peptide

Evidence topic

Insulin Resistance

Primary intervention

GIP

Primary outcomes

C-peptide
Blood glucose
Total GIP

Evidence topics

Insulin Resistance C-Peptide Fasting Blood Glucose Glycemic Control

Primary intervention

GIP

Primary outcomes

C-peptide Blood glucose Total GIP

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

Why it is useful

Contributes to 7 evidence relationships
Includes primary outcome data
Linked to 7 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and Fasting Glucose

Related evidence

Evidence topic

Insulin Resistance

Save evidence

Evidence topic

C-Peptide

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

C-peptide

GIP → C-peptide

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 25; Negative
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Blood glucose

GLP-1 receptor agonists → Blood glucose

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Total GIP

GLP-1/GIP Combination → Total GIP

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Total GLP-1

GLP-1/GIP Combination → Total GLP-1

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Insulin clearance

Metformin → Insulin clearance

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Total insulin secretion

Metformin/Sitagliptin Combination → Total insulin secretion

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Insulin clearance

Sitagliptin → Insulin clearance

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Suggest

Insulin clearance differed significantly between sitagliptin and metformin (p < 0.02).
Total insulin secretion increased significantly during OGTT (p < 0.0001).
Plasma glucose levels decreased significantly during the intervention.

Who this applies to

Adults diagnosed with type 2 diabetes.
Participants undergoing treatment with incretin-based therapies.

Keep in Mind

Results may not apply to populations outside the study's demographics.
Findings are based on a specific set of interventions and may not generalize to all diabetes treatments.
Further studies are needed to explore long-term effects and broader applications.

Between the Lines

Limited sample size may affect generalizability.
Short duration of the study may not capture long-term effects.
Potential confounding factors were not fully controlled.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Metformin Therapies and Insulin Resistance, GIP and C-peptide Levels.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

Metformin Therapies → Insulin Resistance

Medications

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 4 studies
ImpactScore™: 75; Positive
ConsistencyScore™: 35; mixed

Based on 4 studies

View evidence

Medications

Detailed evidence

GIP → C-peptide Levels

Medications

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 25; Negative
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

View evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

Insulin Resistance Evidence Hub

All studies measuring Insulin Resistance

4 studies

outcome_hub

Measures Insulin Resistance as a key outcome.

Metformin Therapies Evidence Hub

All studies on Metformin Therapies

4 studies

intervention_hub

Contributes to Metformin Therapies evidence base.

C-peptide Levels Evidence Hub

All studies measuring C-peptide Levels

1 studies

outcome_hub

Measures C-peptide Levels as a key outcome.

GIP Evidence Hub

All studies on GIP

1 studies

intervention_hub

Contributes to GIP evidence base.

Explore more in Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Metformin and Insulin sensitivity

Intervention: MetforminOutcome: Insulin sensitivity

4 results

All studies on GIP and C-peptide

Intervention: GIPOutcome: C-peptide

1 results

All studies on Metformin

Intervention: Metformin

4 results

All studies on GIP

Intervention: GIP

1 results

All studies measuring Insulin sensitivity

Outcome: Insulin sensitivity

4 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists improve fasting glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve fasting glucose.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
Blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 18 supporting studies with generally consistent results and a positive effect signal.

View Full Evidence

Does GLP-1/GIP Combination improve total gip?

Emerging Evidence

GLP-1/GIP Combination appears to improve total gip.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Total GIP
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does GLP-1/GIP Combination improve total glp-1?

Emerging Evidence

GLP-1/GIP Combination appears to improve total glp-1.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Total GLP-1
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does Metformin/Sitagliptin Combination improve total insulin secretion?

Emerging Evidence

Metformin/Sitagliptin Combination appears to improve total insulin secretion.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Total insulin secretion
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Insulin Resistance Evidence Hub C-Peptide Evidence Hub Fasting Blood Glucose Evidence Hub Glycemic Control Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on GIP and C-peptide All studies on GLP-1 receptor agonists and Blood glucose All studies on GLP-1/GIP Combination and Total GIP All studies on GLP-1/GIP Combination and Total GLP-1

Related research

Read related research summaries.

Dietary Modulation of Gut Microbiota in Prediabetes Sitagliptin improves kidney function in type 1 diabetes Vildagliptin and Metformin Improve Glycemic Control in Type 2 Diabetes Early use of effective therapies may improve diabetes outcomes Metformin improves glycemic control in adolescents with type 1 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.